Carolina Reduzzi, Chief Operating Officer & Treasurer – Non-profit at Precision Medicine Action for Cancer (PMAC), shared a post on LinkedIn:
“In the past months I had the pleasure to co-edit with Lorenzo Gerratana and Letizia Pontolillo a special issue on the use of liquid biopsy for early-stage cancer.
What is this collection about?
Our curated research topic explores the vital shift of liquid biopsy from late-stage monitoring into early disease management. The contributing articles dive deep into:
- Early Detection and Cancer Interception: Catching molecular signals before clinical manifestation.
- Minimal Residual Disease (MRD): Pinpointing trace recurrence risk to guide proactive, individualized care.
A massive thank you to all the brilliant authors and researchers who contributed to this special issue!
Read our editorial and explore the full collection here.”
Title: Early detection, cancer interception, et al.: translating the multifaceted use of liquid biopsy to the management of early disease
Authors: Letizia Pontolillo, Lorenzo Gerratana, Carolina Reduzzi
Read the article: here.
Other articles about Liquid Biopsy on Oncodaily.